Adult ADHD is real. It is impairing. It is often missed, especially in bright, high-achieving adults, women, and people who learned to compensate for years before finally burning out. But the solution to underdiagnosis cannot be overdiagnosis.
We are now seeing a second problem emerge: rushed adult ADHD evaluations, often completed in 30 to 60 minutes, sometimes based heavily on a brief questionnaire, followed quickly by stimulant prescribing. The patient may leave relieved, validated, and medicated. But if the diagnosis is wrong, that “quick win” can become a long-term clinical problem.
Speed is not the same as accuracy. Convenience is not the same as care. And when controlled substances are involved, a fast assessment can create real harm.
ADHD is not diagnosed by vibe, TikTok, or a five-minute checklist
ADHD is a neurodevelopmental condition. That means it begins in childhood, even when it is not recognized until adulthood. A legitimate adult ADHD assessment must establish that symptoms were present before age 12 and persisted across the lifespan. That requires more than asking, “Do you procrastinate?” or “Do you have trouble focusing?”
Real physician voices, twice a week
Free, and one click to unsubscribe.
Most adults have trouble focusing when they are sleep-deprived, anxious, depressed, traumatized, burned out, overworked, perimenopausal, using cannabis, living on caffeine, or trying to survive modern life with 47 browser tabs open, emotionally and literally.
The clinical question is not simply, “Do you have ADHD symptoms?” The better question is, “Are these symptoms lifelong, developmentally consistent, impairing across multiple settings, and not better explained by something else?” That takes time.
Why childhood history matters
A core part of ADHD diagnosis is establishing a childhood pattern. Many adults seeking evaluation can describe current executive dysfunction clearly: difficulty initiating tasks, chronic lateness, disorganization, procrastination, emotional reactivity, or difficulty following through. But current symptoms alone are not enough.
A careful evaluation asks about school history, report cards, teacher comments, homework patterns, parent-child conflict, social functioning, forgetfulness, impulsivity, emotional regulation, and whether the person was quietly struggling despite appearing “fine.” This is especially important for adults who were bright, anxious, compliant, perfectionistic, or heavily supported by parents. Some never looked disruptive. Some got good grades. Some survived by overcompensating until life became too complex.
But the reverse is also true: Some adults who currently feel scattered did not have childhood ADHD. Their executive dysfunction may be new, episodic, situational, or secondary to another condition. That distinction matters because treatment should follow the actual cause, not the trendiest label.
Collateral information is not optional fluff
Collateral information from a parent, partner, spouse, sibling, or close friend can be clinically invaluable. Patients are not unreliable because they are dishonest. They are human. Memory is imperfect. Insight varies. Shame distorts recall. High-functioning adults often minimize impairment. Others may unintentionally over-identify with ADHD after seeing content online that finally gives language to their distress.
A parent may remember whether symptoms were present in childhood. A partner may describe daily impairment the patient has normalized. A spouse may notice emotional impulsivity, task paralysis, financial disorganization, chronic unfinished projects, or patterns of relational strain. A collateral form can reveal patterns the patient does not recognize, or confirm that the issue is broader than attention alone.
When possible, adult ADHD evaluations should include collateral data. Not because the adult needs permission to have ADHD, but because diagnosis improves when we widen the lens.
Psychometric tools help, but they do not replace clinical judgment
Rating scales are useful. They are not diagnostic by themselves. In my own process, I use multiple psychometric instruments because ADHD rarely travels alone. A high-quality assessment should screen not only for ADHD symptoms, but also for anxiety, depression, trauma, autism, sleep problems, substance use, emotional dysregulation, and functional impairment.
I also use the DIVA-5. The DIVA-5 is one of the strongest tools available for adult ADHD assessment because it is a structured, clinician-administered 90-to-120-minute interview based on DSM-5 criteria. It examines both childhood and adult symptoms and asks for real-life examples of impairment. It slows the process down in the exact way that improves diagnostic accuracy.
A questionnaire can tell you what someone endorses. A structured diagnostic interview helps determine what those symptoms mean. That is the difference between collecting symptoms and making a diagnosis.
The comorbidity problem: ADHD has many look-alikes
Adult ADHD often overlaps with other conditions. Anxiety can look like inattention. Depression can look like low motivation. Trauma can look like distractibility, emotional reactivity, or hypervigilance. Autism can look like executive dysfunction and social burnout. Sleep apnea, insomnia, thyroid disease, iron deficiency, hormonal changes, cannabis use, and chronic stress can all impair attention and working memory.
This is where rushed assessments fail. If the entire visit is built around confirming ADHD, the clinician may miss the actual medical or psychiatric diagnosis. Or they may diagnose ADHD correctly but miss the comorbidities that determine the safest and most effective treatment plan. That matters because stimulants may improve focus while worsening anxiety, insomnia, panic, irritability, tics, appetite suppression, blood pressure, or mood instability in vulnerable patients.
A correct diagnosis is not just about access to medication. It is about choosing the right treatment sequence.
Stimulants are helpful for ADHD. That does not make them harmless
For people with true ADHD, stimulant medication can be life-changing. It can reduce impairment, improve follow-through, decrease impulsivity, and help people function closer to their actual capacity. But stimulants are controlled substances for a reason.
They increase dopamine and norepinephrine signaling. They can raise heart rate and blood pressure. They can worsen insomnia and anxiety. They can trigger irritability, appetite suppression, misuse, dependence, diversion, and in some cases psychiatric destabilization. In vulnerable individuals, stimulants can contribute to mania, psychosis, paranoia, or dangerous patterns of escalating use.
The risk-benefit equation looks very different when a person has ADHD versus when they are taking stimulants for cognitive enhancement, productivity pressure, fatigue, burnout, or “I just need to get more done.” Prescribing stimulants to someone without ADHD is not benign. It may temporarily improve performance, but it can also train the brain and behavior around artificial urgency, dopamine-seeking, and medication-dependent productivity. The goal of psychiatric care should not be to help people tolerate unsustainable lives by pharmacologically overriding exhaustion.
Stimulants are not the only option
Another problem with rushed ADHD care is the assumption that diagnosis should automatically lead to a stimulant prescription. Stimulants can be highly effective for appropriately diagnosed ADHD, but they are not the only evidence-based option. Non-stimulant medications can be very helpful, especially for patients with anxiety, insomnia, mood instability, substance-use risk, cardiovascular concerns, stimulant sensitivity, or a preference to avoid controlled substances.
Atomoxetine, known as Strattera, and viloxazine ER, known as Qelbree, are FDA-approved non-stimulant options for adult ADHD. They work more gradually than stimulants and primarily target norepinephrine pathways, which can support attention, impulse control, and emotional regulation without the same misuse or dependence concerns. Alpha-2A adrenergic medications such as guanfacine ER can also be useful, particularly when emotional reactivity, rejection sensitivity, hyperarousal, impulsivity, sleep disruption, or nervous-system overactivation are part of the picture. Bupropion, known as Wellbutrin, is commonly used off-label and may be especially helpful when ADHD symptoms overlap with depression, low motivation, fatigue, or nicotine dependence. Some SNRIs, such as venlafaxine or duloxetine, may also help certain patients with attention, energy, and executive functioning, particularly when anxiety, depression, chronic pain, or perimenopausal symptoms are part of the clinical picture. Newer and emerging medications are also being studied, including agents designed to target norepinephrine, dopamine, and serotonin pathways without being traditional stimulants.
The point is not that non-stimulants are always better. They are usually slower and may be less immediately noticeable than stimulants. The point is that thoughtful ADHD treatment should include a real medication discussion, not a reflexive jump from “I can’t focus” to “Here is Adderall.” Good prescribing means matching the treatment to the person, their risks, their comorbidities, their goals, and their nervous system.
What this looks like in real life
In clinical practice, these are not abstract concerns. I have seen adults who initially sought stimulant medication because pressure was building at work, their focus was slipping, and Adderall sounded like a reasonable solution. They were not trying to misuse medication. They were trying to function.
One de-identified composite example is a woman in her early 30s who started Adderall during the pandemic. Like many people at that time, she was under significant stress, working in an altered environment, isolated from normal routines, and trying to keep up with escalating demands. A stimulant seemed like a practical answer. At first, it helped.
But over several years, the picture changed. Her sleep gradually worsened. Her irritability increased. She became more anxious and ruminative. Her dose continued to climb until she was taking 60 mg per day. What began as “I need help focusing” slowly evolved into significant anxiety, mood symptoms, and paranoid thoughts, including fears that food at her local grocery store might be contaminated or intentionally poisoned. Her relationships suffered. She lost friendships. Her partner experienced her as increasingly critical, tense, and emotionally reactive. She was not becoming a “bad person.” Her nervous system was becoming overstimulated, sleep-deprived, anxious, and dysregulated.
By the time she came into care, the issue was no longer simply attention. It was the cumulative effect of years of stimulant exposure in a person whose original symptoms may have been driven more by stress, burnout, mood vulnerability, and executive overload than by clearly established ADHD. We tapered the stimulant slowly over nine months while supporting mood stability, sleep, and nervous system regulation. The change was not instant, but it was meaningful. She began sleeping eight hours a night. Her anxiety softened. Her mood improved. She became less reactive and more herself. She returned to tennis, started socializing again, and rebuilt the warmth, ease, and emotional connection that had once been present in her relationship.
That is the part of this conversation that often gets missed. The risk is not only addiction in the dramatic, stereotyped sense. The risk can be quieter: chronic sleep erosion, escalating dose tolerance, irritability, anxiety, obsessive rumination, emotional constriction, relationship strain, and a gradual loss of the person’s baseline sense of self. When stimulants are prescribed without a careful diagnostic process, patients may spend years treating the wrong problem and paying for it in their bodies, relationships, and mental health.
The other side of the problem: Patients with real ADHD are being shamed
There is another consequence of sloppy stimulant prescribing that does not get enough attention: it hurts patients with legitimate ADHD. I have also seen patients with carefully established ADHD who have taken stimulant medication responsibly for years, only to be treated with suspicion and humiliation because the broader prescribing culture has become so chaotic.
One patient came to me after years of taking Adderall appropriately. She wanted to transition to a non-stimulant medication and reduce her stimulant use safely. This was not a patient asking for higher doses. She was asking for a careful taper. She had moved, transferred to a new pharmacy, and expected the prescription to be handled professionally. Instead, the pharmacist treated her like a criminal.
He refused to fill the prescription unless he received a copy of my controlled substance agreement with her, including documentation that she had consented to taper stimulants and that we would only be decreasing the dose, not increasing it. The request itself could have been handled through a private professional conversation between the pharmacy and the prescriber. That was not what happened. He discussed it in front of a line of waiting customers. He humiliated her publicly. The shame was so intense that she wanted to stop Adderall cold turkey, despite the fact that stopping abruptly would have been clinically risky given her mood instability.
This is what happens when a system loses trust. Patients with real ADHD become collateral damage. They are treated as suspicious before they are treated as patients. They are forced to defend their diagnosis, their prescription, and their character at the pharmacy counter. Meanwhile, many are already carrying years of shame from being called lazy, scattered, dramatic, irresponsible, or “too much.”
We cannot ignore this. Overdiagnosis and careless stimulant prescribing do not make care easier for patients with ADHD. They make it harder. They increase stigma, pharmacist scrutiny, access barriers, and fear. They create an environment where responsible patients are punished for the behavior of irresponsible systems.
The rise of cognitive enhancement culture
We need to talk honestly about the culture surrounding adult stimulant use. Many adults are not seeking intoxication. They are seeking survival. They are overwhelmed, overextended, sleep-deprived, digitally fragmented, financially stressed, and expected to produce at machine speed. In that environment, stimulants can become performance tools rather than medical treatment.
This is cognitive enhancement culture: the idea that normal human limits are flaws to be medicated. Can’t focus after sleeping five hours? Medicate. Burned out from an impossible workload? Medicate. Can’t keep up with emails, parenting, charting, school, bills, texts, and the emotional labor of being alive? Medicate. This is not health care. It is capitalism with a prescription pad.
The danger is that real ADHD gets trivialized while non-ADHD distress gets mislabeled. The people who genuinely need medication then face more stigma, more scrutiny, and more shortages.
Telehealth, pill mills, and the cost of bad incentives
Telehealth can be excellent. It improves access, especially for patients in rural areas, people with disabilities, parents, and adults whose executive dysfunction makes traditional health care difficult to access. The problem is not telehealth itself. The problem is poor clinical standards combined with business models that reward speed, volume, retention, and prescriptions.
Companies such as Cerebral and Done became cautionary examples of what happens when ADHD care is scaled like a subscription product. Federal investigations and legal actions raised concerns about business practices that encouraged stimulant prescribing, short evaluations, inadequate examination, and prescriptions that allegedly were not always issued for legitimate medical purposes. This should alarm every ethical clinician.
When ADHD assessment becomes a cash-pay pipeline to stimulants, the diagnosis itself is cheapened. Patients become consumers. Prescribers become throughput engines. Medication becomes the product. That is not psychiatric care.
The medication shortage is also an ethics issue
Stimulant shortages have harmed patients with legitimate ADHD who rely on these medications to function. Many patients have spent months calling pharmacies, rationing medication, changing formulations, missing work, struggling at school, or destabilizing because they cannot access a medication that was previously effective and appropriate.
Overprescribing is not the only cause of medication shortages, but it is part of the ethical conversation. Every unnecessary prescription increases pressure on a limited supply. Every sloppy diagnosis makes pharmacists more suspicious. Every pill-mill scandal creates more regulatory backlash. And the people who pay the highest price are often the patients with carefully diagnosed ADHD who are using medication responsibly.
Medication is not the whole treatment plan
Even when ADHD is correctly diagnosed, stimulants are not the whole plan. Adults with ADHD often need skills, structure, environmental design, therapy, coaching, accountability systems, sleep stabilization, nervous system regulation, and practical supports. Medication may help the brain engage, but systems help the person function.
A strong ADHD treatment plan should ask:
- What breaks down in daily life?
- Where does the person need scaffolding?
- What systems can reduce working-memory load?
- What routines are realistic?
- What emotional patterns derail follow-through?
- What role do sleep, nutrition, trauma, anxiety, sensory overwhelm, or burnout play?
- What support does the partner, family, workplace, or school need to understand?
The most effective care does not simply ask, “Which stimulant and what dose?” It asks, “How do we build a life that works with this nervous system?”
Getting it right matters more than getting it fast
A comprehensive adult ADHD assessment is not gatekeeping. It is good medicine. It protects patients from misdiagnosis. It protects stimulant access for people who truly need it. It identifies comorbidities that shape treatment. It reduces misuse and diversion. It helps clinicians prescribe with confidence. And it gives patients something more valuable than a label: a clear, accurate understanding of how their brain works.
Quick assessments may feel efficient. But when the diagnosis is complex and the medication has real risks, speed can become negligence wearing a productivity costume. Adult ADHD deserves serious assessment. Patients deserve more than a checklist. And controlled substances deserve more than a 30-minute sales funnel.
The standard should be simple: Diagnose carefully, prescribe thoughtfully, monitor responsibly, and treat the whole person, not just the symptom that fits neatly into a billing code.
Carrie Friedman is a dual board-certified psychiatric and family nurse practitioner and the founder of Brain Garden Psychiatry in California. She integrates evidence-based psychopharmacology with functional and integrative psychiatry, emphasizing root-cause approaches that connect neuro-nutrition and gut–brain science, metabolic psychiatry, immunology, endocrinology, and mind–body lifestyle medicine. Carrie’s clinical focus bridges conventional psychiatry with holistic strategies to support mental health through nutrition, physiology, and sustainable lifestyle interventions. Her professional writing explores topics such as functional medicine, autism, provider well-being, and medical ethics.
